Suppr超能文献

用利血平和垂体照射治疗库欣病。

Treatment of Cushing's disease with reserpine and pituitary irradiation.

作者信息

Miura K, Aida M, Mihara A, Kato K, Ojima M

出版信息

J Clin Endocrinol Metab. 1975 Sep;41(3):511-26. doi: 10.1210/jcem-41-3-511.

Abstract

Eighteen patients with Cushing's disease were treated with reserpine and pituitary irradiation. Complete remission was obtained in 9 out of 18 patients after reserpine treatment of 1-2 mg per day for a mean period of 20.4 months, and pituitary irradiation with a mean of 5,865 rads. In another 9 patients, reserpine 0.8-2 mg per day for a mean period of 22.5 months, and pituitary irradiation with a mean of 6,650 rads, were employed. Of these 9 patients, an additional subtotal adrenalectomy was carried out in 6 patients who are now in complete remission. Because of severe psychic symptoms resulted from the original disease in 2 of the remaining 3 patients, subtotal adrenalectomy was performed first and pituitary irradiation and reserpine treatment followed. Remission was eventually obtained in these 2 cases. One patient refused the operation, and thus had little clinical remission. All of the 17 cases in remission were followed up for periods of 6 months to 10 yr. During this time, only one case which had responded to reserpine and pituitary irradiation relapsed, but regained remission following resumption of therapy. Another died of cerebral glioblastoma 4 yr after remission of the disease. It was noteworthy that endocrinologic data including: plasma levels of ACTH and 11-OHCS, suppressibility by dexamethasone, responses of plasma GH to arginine and to insulin loads, and diurnal rhythm of plasma 11-OHCS were nearly normal in a considerable number of the cases in remission. Effectiveness of the combined therapy with reserpine and pituitary irradiation for treating Cushing's disease may support a working hypothesis that reserpine acts through some as yet unknown mechanism to correct a presumed central nervous disorder, while suitable pituitary irradiation probably corrects the pituitary dysfunction directly.

摘要

18例库欣病患者接受了利血平和垂体照射治疗。18例患者中,9例患者每日服用1 - 2毫克利血平,平均治疗20.4个月,同时平均接受5865拉德的垂体照射后获得完全缓解。另外9例患者,每日服用0.8 - 2毫克利血平,平均治疗22.5个月,平均接受6650拉德的垂体照射。在这9例患者中,6例患者额外进行了次全肾上腺切除术,目前已完全缓解。其余3例患者中有2例因原发病导致严重精神症状,先行次全肾上腺切除术,随后进行垂体照射和利血平治疗。这2例最终获得缓解。1例患者拒绝手术,因此几乎没有临床缓解。所有17例缓解患者的随访时间为6个月至10年。在此期间,只有1例对利血平和垂体照射有反应的患者复发,但恢复治疗后再次缓解。另1例在疾病缓解4年后死于脑胶质母细胞瘤。值得注意的是,包括促肾上腺皮质激素(ACTH)和11 - 羟皮质类固醇(11 - OHCS)血浆水平、地塞米松抑制试验、血浆生长激素(GH)对精氨酸和胰岛素负荷的反应以及血浆11 - OHCS的昼夜节律在内的内分泌学数据,在相当多的缓解病例中几乎正常。利血平和垂体照射联合治疗库欣病的有效性可能支持一个工作假设,即利血平通过某种未知机制发挥作用,纠正假定的中枢神经系统紊乱,而适当的垂体照射可能直接纠正垂体功能障碍。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验